| Not Yet Recruiting | Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Synd NCT07468916 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and My NCT07228624 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS NCT07270978 | University of Virginia | Phase 1 |
| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) NCT06661915 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Ne NCT06523556 | Uma Borate | Phase 1 / Phase 2 |
| Recruiting | A Telehealth Advance Care Planning Intervention NCT05875805 | University of Rochester | N/A |
| Active Not Recruiting | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagno NCT06034470 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodys NCT05600894 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloprolifera NCT05038592 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms NCT04902833 | Massachusetts General Hospital | — |
| Recruiting | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CM NCT04771572 | Newave Pharmaceutical Inc | Phase 1 |
| Recruiting | A Study of BGB-11417 in Participants With Myeloid Malignancies NCT04771130 | BeiGene | Phase 1 / Phase 2 |
| Completed | Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/ NCT04926194 | University Health Network, Toronto | Phase 2 |
| Terminated | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neop NCT04637009 | Astex Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant NCT03964506 | Omar Aljitawi | EARLY_Phase 1 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Withdrawn | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT04022785 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Tran NCT03560752 | City of Hope Medical Center | Phase 1 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Terminated | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or NCT02666950 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferati NCT02257138 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Unknown | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leuke NCT01894477 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia NCT01712308 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478 | Fred Hutchinson Cancer Center | Phase 3 |
| Completed | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Ce NCT00096161 | Fred Hutchinson Cancer Center | Phase 2 |